Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-08-07

Tempus AI, Inc.

Tempus provides oncology and hereditary molecular testing, clinical data products, trial matching, and workflow software to providers, payers, researchers, and biopharma.

ai biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From premium lab to oncology workflow rail

The upside case is that diagnostic volume becomes the fuel for a broader, higher-margin oncology data and action layer. The stock can compound well if reimbursement lifts core assay economics and software-plus-data becomes a larger share of gross profit.

Analysis

Thesis

Tempus can outgrow normal diagnostics peers by turning test volume, embedded provider workflows, and reimbursement wins into a higher-margin oncology data-and-action platform; if MRD, ADLT pricing migration, and Data & Applications scale together, equity compounding can track the bullish end of consensus without requiring a pure-software fantasy multiple.

Last Economy Alignment

Tempus benefits as AI makes interpretation cheaper because it owns regulated tests, proprietary multimodal data, and workflow placement inside oncology care. Its capture is less exposed to seat-price collapse than pure software, and agent bypass risk is moderated by EHR embedment and clinical trust requirements.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

The upside is a business-mix upgrade, not magic. Core diagnostics should grow with oncology volume, MRD broadens the care continuum, reimbursement lifts assay economics, and Data & Applications becomes a larger share of gross profit. That can support a modest premium revenue multiple in 2031, but payer gates and clinical deployment cycles should still keep the stock below pure software valuations.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is that Tempus improves operationally yet remains valued mainly as a premium diagnostics company. If reimbursement uplift is slower, Personalis integration is messy, or Data & Applications does not become a much larger profit pool, margin gains may be real but insufficient to sustain a durable platform premium.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On July 30, 2026, second-quarter results showed revenue of 382.5 and positive Adjusted EBITDA of 8.0, strengthening the year-end cash-generation path.
On July 30, 2026, management guided to 1595.0-1605.0 of 2026 revenue and roughly 65.0 of Adjusted EBITDA, firming the near-term execution floor.
On August 4, 2026, Tempus highlighted a new PRISM2 publication, adding evidence that its multimodal model layer has clinical relevance, though monetization remains indirect today.

Thesis update

No structural thesis change; recent evidence mainly increased confidence that the core engine is scaling while the reimbursement-led economics unlock remains intact.

Forecast update

Slightly better proof on margin progression and cash generation supports a firmer terminal view, but the core upside still depends on the same mix-shift mechanics.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.64

They sit inside cancer testing and care workflows, so every new test creates data that can make their software and pharma tools better. AI helps them more than it hurts, but reimbursement rules and data-rights limits still control how much value they can keep.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$62.64

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research